The implications of prostate-specific antigen density to predict clinically significant prostate cancer in men <= 50 years

被引:0
|
作者
Kosaka, Takeo [1 ]
Mizuno, Ryuichi [1 ]
Shinojima, Toshiaki [1 ]
Miyajima, Akira [1 ]
Kikuchi, Eiji [1 ]
Tanaka, Nobuyuki [1 ]
Shinoda, Kazunobu [1 ]
Morita, Shinya [1 ]
Mikami, Shuji [2 ]
Oya, Mototsugu [1 ]
机构
[1] Keio Univ, Sch Med, Dept Urol, Tokyo, Japan
[2] Keio Univ, Sch Med, Dept Pathol, Tokyo, Japan
来源
AMERICAN JOURNAL OF CLINICAL AND EXPERIMENTAL UROLOGY | 2014年 / 2卷 / 04期
关键词
Prostate cancer; prostate biopsy; PSA density; insignificant prostate cancer;
D O I
暂无
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
To investigate the appropriate cut-off level of PSA or other clinical parameters at aged <= 50 years. The rate of detection of PCa in young men will continue to rise associated with the advancement of the current and evolving practices of screening and detection. In this study, we determined whether to investigate the appropriate cut-off level of PSA or other clinical parameters at aged <= 50 years. The study population included 106 patients aged <= 50 years who had prostate biopsy at our institute. The differences of clinical variables including various PSA related parameters between the patients with significant PCa and insignificant PCa were analyzed. Receiver operating characteristics (ROC) curves and the corresponding areas under the ROC curves (AUC) were calculated. There were no significant differences between no-PCa and PCa patients regarding PSA value, prostate volume (P vol), PSA density (PSAD), transition zone volume (TZ vol), PSATZ density (PSATZD). When the patients meeting the following criteria, Gleason score was <= 6 with less than 2 positive biopsy cores, were classified as having insignificant prostate cancer, PSAD could become a useful predictor of significant PCa in men. The AUC was significantly greater in PSAD (0.801) than for the other parameters. The sensitivity and specificity of a PSAD threshold of 0.32 were 85.7% and 77.8%, respectively. In conclusion, PSAD can be a useful and very effective predictor in a man aged <= 50 and we can counsel patients with discretion regarding the likelihood of significant PCa.
引用
收藏
页码:332 / 336
页数:5
相关论文
共 50 条
  • [1] The use of prostate specific antigen density to predict clinically significant prostate cancer
    Yusim, Igor
    Krenawi, Muhammad
    Mazor, Elad
    Novack, Victor
    Mabjeesh, Nicola J.
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [2] Consistent predictive ability of prostate-specific antigen density prediction model for clinically significant prostate cancer across age strata
    Malshy, Kamil
    Ochsner, Anna
    Homer, Alexander
    Allu, Sai
    Passarelli, Natalie
    Sojka, Andrew
    Glebocki, Richard
    Golijanin, Borivoj
    Ortiz, Rebecca
    Eaton, Samuel
    Pareek, Gyan
    Khaleel, Sari
    Golijanin, Dragan
    Hyams, Elias
    PROSTATE, 2024, 84 (13) : 1209 - 1217
  • [3] The performance characteristics of prostate-specific antigen and prostate-specific antigen density in tOChinese men
    Teoh, Jeremy Y. C.
    Yuen, Steffi K. K.
    Tsu, James H. L.
    Wong, Charles K. W.
    Ho, Brian S. H.
    Ng, Ada T. L.
    Ma, Wai-Kit
    Ho, Kwan-Lun
    Yiu, Ming-Kwong
    ASIAN JOURNAL OF ANDROLOGY, 2017, 19 (01) : 113 - 116
  • [4] Combining prostate-specific antigen density with prostate imaging reporting and data system score version 2.1 to improve detection of clinically significant prostate cancer: A retrospective study
    Lei, Yin
    Li, Tian Jie
    Gu, Peng
    Yang, Yu Kun
    Zhao, Lei
    Gao, Chao
    Hu, Juan
    Liu, Xiao Dong
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [5] THE EFFECTIVENESS OF PROSTATE SPECIFIC ANTIGEN DENSITY IN PREDICTING PROSTATE CANCER AND CLINICALLY SIGNIFICANT PROSTATE CANCER IN PATIENTS AGED 70 YEARS AND OVER
    Avci, Sinan
    Caglayan, Voikan
    Onen, Efe
    Kilic, Metin
    Gul, Abdullah
    Oner, Sedat
    TURKISH JOURNAL OF GERIATRICS-TURK GERIATRI DERGISI, 2020, 23 (02): : 197 - 205
  • [6] Prostate cancer in 432 men aged &lt;50 years in the prostate-specific antigen era: a new outlook
    Gielchinsky, Ilan
    Chang, John
    Cusick, Thomas
    Delprado, Warick
    Quoc Nguyen
    Yuen, Carlo
    Savdie, Richard
    Bohm, Maret
    Haynes, Anne-Maree
    Scheltema, Matthijs J.
    Stricker, Phillip D.
    BJU INTERNATIONAL, 2018, 122 : 35 - 41
  • [7] Clinically Significant Prostate Cancer Diagnosis Without Histological Proof: A Possibility in the Prostate-specific Membrane Antigen Era?
    Heetman, Joris G.
    Wever, Lieke
    Pereira, Leonor J. Paulino
    van den Bergh, Roderick C. N.
    EUROPEAN UROLOGY OPEN SCIENCE, 2022, 44 : 30 - 32
  • [8] Body mass index does not predict prostate-specific antigen or percent free prostate-specific antigen in men undergoing prostate cancer screening
    Hutterer, Georg
    Perrotte, Paul
    Gallina, Andrea
    Walz, Jochen
    Jeldres, Claudio
    Traumann, Miriam
    Suardi, Nazareno
    Saad, Fred
    Benard, Francois
    Valiquette, Luc
    McCormack, Michael
    Graefen, Markus
    Montorsi, Francesco
    Karakiewicz, Pierre I.
    EUROPEAN JOURNAL OF CANCER, 2007, 43 (07) : 1180 - 1187
  • [9] MRI Fusion-Targeted Transrectal Prostate Biopsy and the Role of Prostate-Specific Antigen Density and Prostate Health Index for the Detection of Clinically Significant Prostate Cancer in Southeast Asian Men
    Tan, Teck Wei
    Png, Keng Siang
    Lee, Chau Hung
    Yuwono, Arianto
    Yeow, Yuyi
    Chong, Kian Tai
    Lee, Yee Mun
    Tan, Cher Heng
    Tan, Yung Khan
    JOURNAL OF ENDOUROLOGY, 2017, 31 (11) : 1111 - 1116
  • [10] Comparison of 6- and 12-Core Prostate Biopsy in Taiwanese Men: Impact of Total Prostate-Specific Antigen, Prostate-Specific Antigen Density and Prostate Volume on Prostate Cancer Detection
    Chiang, I-Ni
    Chang, Shang-Jen
    Pu, Yeong-Shiau
    Huang, Kuo-How
    Yu, Hong-Jen
    Huang, Chao-Yaun
    UROLOGIA INTERNATIONALIS, 2009, 82 (03) : 270 - 275